Resolving disease
Promoting host defense
Pioneering Resolution Therapy
Thetis is a clinical-stage pharmaceutical company developing TP-317 for treating inflammatory bowel disease (IBD) and solid tumor cancers ─ without immunosuppression.
TP-317 is a Resolvin E1 (RvE1) drug that promotes tissue and immune homeostasis via the BLT1 receptor.
Discovered in 2000, Resolvin E1 (RvE1) is a potent lipid mediator that activates natural resolution pathways. Until the discovery of TP-317, clinical development of RvE1 was blocked by its poor stability and lack of an oral formulation. Our breakthrough technology overcomes these hurdles for development of RvE1 therapeutics.
In a Phase 1a in healthy volunteers, oral TP-317 was well-tolerated and demonstrated target engagement. A 12-week proof-of-mechanism study in moderate-to-severe ulcerative colitis patients is scheduled to begin in 2026.